Publikation
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Wissenschaftlicher Artikel/Review - 09.02.2023
Çakar Esra, Oniangue-Ndza César, Schneider Ralph P, Klijn Sven L, Vogl Ursula M, Rothermundt Christian, May Jessica R
Bereiche
PubMed
DOI
Kontakt
Zitation
Çakar E, Oniangue-Ndza C, Schneider R, Klijn S, Vogl U, Rothermundt C, May J. Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. Pharmacoecon Open 2023
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Pharmacoecon Open 2023
Veröffentlichungsdatum
09.02.2023
eISSN (Online)
2509-4254
Kurzbeschreibung/Zielsetzung
This study assessed the cost-effectiveness of nivolumab plus ipilimumab versus both sunitinib and pazopanib for the treatment of first-line unresectable advanced renal cell carcinoma (aRCC) from a healthcare system perspective in Switzerland.